ARTICLE

www.rsc.org/obc

A novel approach of cycloaddition of difluorocarbene to α , β -unsaturated aldehydes and ketones: synthesis of *gem*-difluorocyclopropyl ketones and 2-fluorofurans

Wei Xu and Qing-Yun Chen*

Laboratory of Organofluorine Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, 354 Fenglin Lu, 200032 Shanghai, China. E-mail: chenqy@pub.sioc.ac.cn

Received 12th December 2002, Accepted 19th February 2003 First published as an Advance Article on the web 11th March 2003

A series of *gem*-difluorocyclopropyl acetals and ketals are easily obtained in moderate yields from the [1+2] cycloaddition of difluorocarbene to 1,3-dioxolanes of α , β -unsaturated aromatic aldehydes and ketones. Hydrolysis of these fluorinated compounds under acidic conditions either gives the corresponding *gem*-difluorocyclopropyl ketones or 1-aryl-2-fluorofuran derivatives through intramolecular carbonium rearrangement with simultaneous ring cleavage.


Introduction

Difluorocarbene addition to an olefin is a fundamental reaction for the preparation of difluorocyclopropane derivatives.1 Although electron-rich alkenes react readily with difluorocarbene under mild conditions, there are only a few difluorocarbene reagents that have been found to react with electron-deficient alkenes to give reasonable yields of gemdifluorocyclopropanes.² Using electron-poor steroidal enones and dienones, Beard et al. first carried out their cycloaddition with difluorocarbene generated from high temperature (150-180 °C) thermolysis of a large excess (50 equiv.) of sodium chlorodifluoroacetate.³ Due to the inconvenience and low yields of this method, Kobayashi et al. prepared gem-difluorocyclopropyl ketones through a three-step procedure, *i.e.* addition of difluorocarbene to the allyl acetate, alkaline hydrolysis and Jones oxidation, instead of the direct difluoromethylenation of α,β -unsaturated ketones.⁴ Recently, a highly efficient diffuorocarbene precursor, FSO₂CF₂COOSiMe₃ (TFDA) was reported, by which an unprecedented difluorocarbene addition to electron-poor *n*-butyl acrylate proceeded in 73% yield.⁵ The superiority of the new reagent over ClCF₂COONa was also demonstrated in the synthesis of bis- and oligo-gem-difluorocyclopropanes.⁶ However, we found that TFDA did not react with α , β -unsaturated aldehydes and ketones under the reaction conditions used (i.e. in the presence of 10 mol% of NaF in diglyme at 120 °C).⁷ It is not surprising that the nucleophilic character of the enone carbon-carbon double bond is considerably reduced by electron delocalization with the carbonyl group, resulting in lower reactivity towards the electrophilic difluorocarbene species.8 In order to overcome the difficulty, a protection and deprotection of enone carbonyl group might be an alternative choice.

We, herein, present the results of cycloaddition of difluorocarbene generated from decomposition of TFDA to protected α , β -unsaturated aldehydes and ketones followed by deprotection with acidic hydrolysis.

Results and discussion


Treatment of 1,3-dioxolanes of α , β -unsaturated aromatic aldehydes and ketones (1) with TFDA (3 equiv.) in diglyme in the presence of 10 mol% anhydrous NaF at 110–130 °C for about 2 h gave the corresponding [1+2] adducts (2) in moderate to good yields (Scheme 1).



 $\begin{array}{lll} \textbf{Scheme 1} & X = H, R = H (\textbf{a}); X = Cl, R = H (\textbf{b}); X = CH_3O, R = H (\textbf{c}); \\ X = CH_3, R = H (\textbf{d}); X = CF_3, R = H (\textbf{e}); X = H, R = CH_3 (\textbf{f}); X = Cl, \\ R = CH_3 (\textbf{g}); X = CH_3O, R = CH_3 (\textbf{h}); X = CH_3, R = CH_3 (\textbf{i}); X = CF_3, \\ R = CH_3 (\textbf{j}); X = CH_3O, R = C_6H_5 (\textbf{k}); X = CH_3, R = C_6H_5 (\textbf{l}); X = H, \\ R = C_6H_5 (\textbf{m}); X = Cl, R = C_6H_5 (\textbf{n}); X = CF_3, R = C_6H_5 (\textbf{o}); X = C_6H_5, \\ R = 4\text{-}CH_3-C_6H_4 (\textbf{p}); X = C_6H_5, R = 4\text{-}CH_3-C_6H_4 (\textbf{q}). \end{array}$

The results are listed in Table 1.

Unexpectedly, the following deprotection step was not easy. Employing usual deprotection conditions for 1,3-dioxolanes, *e.g.* HCl-acetone/rt, HCl-methanol/rt, HCl-THF/rt, **2** could not be converted to the corresponding aldehydes and ketones and were recovered completely. Interestingly, it was found that deprotection was achieved by treatment with saturated oxalic acid solution in dioxane at 110 °C for 6 h.⁹ The products based on ¹H, ¹⁹ F NMR, MS as well as elemental analysis were *gem*-diffuorocyclopropyl ketones (**3**) and /or 1-aryl-2-fluorofurans (**4**) (Scheme 2).



The results are listed in Table 2.

Compound **4k** was crystallized from a mixture of petroleum ether and dichloromethane, and its structure was confirmed by single crystal X-ray analysis (Fig. 1).

The results shown in Table 2 demonstrated that the normal products **3** after acidic hydrolysis were obtained for almost all of the β -aryl-*gem*-difluorocyclopropyl ketals (Table 2, entries 13–17) except for those compounds having an electron-donating group (CH₃O, CH₃) on the β -phenyl ring (Table 2, entries 11,12). 1-Aryl-2-fluorofurans (**4**) were the only isolated products derived from the hydrolysis of β -aryl *gem*-difluorocyclopropylacetals (**2**, R = H) (Table 2, entries 1–4) except the compound possessing a strong electron withdrawing group

Entry	Substrate	Х	R	$T/^{\circ}C^{a}$	Time/h	Product	Isolated yield (%)
1	1a	Н	Н	118	1	2a	68
2	1b	Cl	Н	126	2	2b	59
3	1c	CH ₃ O	Н	124	0.5	2c	72
4	1d	CH ₃	Н	120	1	2d	67
5	1e	CF ₃	Н	128	1	2e	51
6	1f	Н	CH ₃	112	0.5	2f	49
7	1g	Cl	CH ₃	118	2	2g	48
8	1ĥ	CH ₃ O	CH ₃	115	0.5	2h	54
9	1i	CH ₃	CH ₃	122	1	2i	62
10	1j	CF ₃	CH ₃	124	2	2j	42
11	1k	CH ₃ O	C ₆ H ₅	120	0.5	2k	61
12	11	CH ₃	C_6H_5	122	1.5	21	65
13	1m	Н	C_6H_5	118	1	2m	42
14	1n	Cl	C_6H_5	128	1	2n	48
15	10	CF ₃	C_6H_5	126	1	20	40
16	1p	C_6H_5	$4-CH_3C_6H_4$	128	0.5	2p	60
17	1q	C_6H_5	4-CH ₃ OC ₆ H ₄	132	2	2q	64

Table 1 Cycloaddition of difluorocarbene to acetals and ketals of α , β -unsaturated aromatic aldehydes and ketones

^a Oil bath temperature

Table 2 Hydrolysis of gem-difluorocyclopropyl acetals and ketals with saturated oxalic acid solution in dioxane at 110 °C for 6 h

Entry	Substrate	Х	R	Product	Yield (%)
 1	2a	Н	Н	4 a	21
2	2b	Cl	Н	4 b	21
3	2c	CH ₃ O	Н	4 c	26
4	2d	CH ₃	Н	4d	27
5	2e	CF_3	Н	4e, 3e	1 (4e), 55 (3e)
6	2f	Н	CH3	4 f	47
7	2g	Cl	CH ₃	4g, 3g	1(4g), 64 (3g)
8	2h	CH ₃ O	CH ₃	4h	52
9	2i	CH ₃	CH ₃	4 i	50
10	2j	CF_3	CH ₃	3j	69
11	2k	CH₃O	C_6H_5	4k	55
12	21	CH ₃	$\tilde{C_6H_5}$	41, 31	15 (4I), 36 (3I)
13	2m	Н	$\tilde{C_6H_5}$	3m	78
14	2n	Cl	$\tilde{C_6H_5}$	3n	54
15	20	CF_3	C ₆ H ₅	30	43
16	2p	C ₆ H ₅	4-CH ₃ C ₆ H ₄	4p, 3p	2(4p), 60(3p)
17	2q	C ₆ H₅	4-CH ₃ OC ₆ H ₄	4q, 3q	2(4q), 58(3q)




Fig. 1 X-Ray structure of 4k. Selected bond lengths (Å), bond angles (°) and torsion angles (°): C (1)–C(2), 1.351(2); C(1)–C(11), 1.4474 (19); C(2)–C(3), 1.391(2); O(1)–C(1), 1.3770(16); O(1)–C(4), 1.3740(16); F–C(2), 1.3525(17); C(2)–C(3), 1.391(2); C(3)–C(4), 1.347(2); C(4)–C(5), 1.4523(19); C(4)–O(1)–C(1), 108.35(11); C(14)–O(2)–C(17), 117.70(13); C(2)–C(1)–O(1), 106.03(12); C(1)–C(2)–F, 124.62(14); F–C(2)–C(3), 124.79(14).

(CF₃) at the *para* position of the β -phenyl ring (Table 2, entry 5), As for the β -aryl-*gem*-difluorocyclopropylmethyl ketals (**2**, **R** = CH₃), the ratio of normal products (**3**) to furan derivatives (**4**) obtained is dependent on the electronic property of the substitute on the β -phenyl ring; *i.e.* for an electron-donating group, furan derivatives (**4**, **R** = CH₃, Table 2, entries 6, 8, 9) were the sole products, whereas for an electron-withdrawing group, the normal ketone was dominantly, if not exclusively, produced (Table 2, entries 5, 7, 10).

All these results might be rationalized as follows: after deprotection of **2**, β -aryl-*gem*-difluorocyclopropyl aldehydes and ketones (**3**) might be protonated on carbonyl oxygen to give a

carbonium ion (3^+) whose reactivity depends on the properties of R and the substituent X on the β -phenyl ring (Scheme 3). The carbocation of aldehyde (R = H) and methyl ketones

 $(R = CH_3)$, (3^+) generated undergoes an intramolecular shift easily with simultaneous collapse of the carbon–carbon bond



Scheme 3 Proposed mechanism.

opposite to the *gem*-diffuoromethyl group¹⁰ followed by an attack of enol oxygen on the resultant carbonium ion **5** (Y = H) to yield β -fluorofuran derivatives after HF elimination (Path a).

An alternative mechanism suggested by one of the referees of this manuscript is that cyclopropane ring opening occurs during the protonation of **2** with the direct formation of a new cation **5** ($Y = CH_2CH_2OH$) instead of **3**⁺ (Path b).

This process, apparently, proceeds readily when the substituent on the β -phenyl ring is an electron-donating or even a weak electron-withdrawing group (X = CH₃, CH₃O, H, Cl). On the contrary, if a strong electron-withdrawing group (X = CF₃, Cl) is present on the β -phenyl ring, the carbocation intramolecular shift does not take place or proceeds with difficultly.

As for the aryl ketones ($\mathbf{R} = C_6\mathbf{H}_5$, p-CH₃C₆H₄, p-CH₃-OC₆H₄), due to the participation of the aryl group, their carbocations ($\mathbf{3}^+$) are stable and do not rearrange, therefore, aryl ketones are regenerated unless an electron-donating group (CH₃, CH₃O) on the β -phenyl ring is present, in which case the β -fluorofuran derivative is also formed and even becomes the only product.

The study on the reaction of simple α , β -unsaturated aliphatic aldehydes and ketones (RCH=CHCRO, R = H, alkyl) with TFDA is in progress.

In conclusion, we have developed a simple method for the synthesis of β -aryl *gem*-diffuorocyclopropyl ketones and 1-aryl-2-fluorofurans from the reactions of protected α , β -unsaturated aldehydes and ketones with an easily available diffuorocarbene precursor, FSO₂CF₂COOSiMe₃.

Experimental section

¹H NMR spectra were recorded with TMS as an internal standard (positive for upfield). ¹⁹F NMR spectra were recorded with CFCl₃ as an external standard (negative for upfield). The solvent for NMR measurement was CDCl₃. Diglyme was dried with sodium, FSO₂CF₂COOSiMe₃ (TFDA) was prepared according to the literature.⁵ Aldehydes are commercially available, whereas all α , β -unsaturated ketones were prepared following published procedures.¹¹ 1,3-Dioxane of α , β -unsaturated aldehydes are prepared according to published methods.^{12,13}

Synthesis of 1,3-dioxane of α,β-unsaturated ketones¹⁴

A typical procedure: in a 250 ml flask equipped with a Dean–Stark adaptor and a condenser was placed 4-phenyl-3-butene-2-one (1.56 g, 10.7 mmol), ethylene glycol (9.3 ml), 2-ethyl-2methyl-1,3-dioxolane¹⁵ (9.3 ml), PTSA (93 mg) and benzene (150 ml). The mixture was heated to reflux for 12 h. After the mixture was cooled to room temperature, saturated Na₂CO₃ (20 ml) was added and stirred for 15 minutes. The organic layer was separated and the aqueous was extracted with ether. The combined organic phase was washed with brine and dried over Na₂SO₄. The solvent was removed and the residue was purified by flash chromatography on a silica gel column. Ketal **1f** was obtained as a pale yellow liquid (1.24 g, 61%) with spectroscopic data identical to that reported previously.¹⁶ Compound **1m** (71% yield) was determined by the published spectroscopic data.¹⁷

Compound **1g**: yellow liquid, 64%. IR (film) (cm⁻¹): 2987, 2885, 1655, 1594, 1492, 1406, 1374, 1215, 1195, 1095, 1043. ¹H NMR (CDCl₃) δ 1.55 (s, 3H), 3.93–4.02 (m, 4H), 6.13 (d, J = 16.2 Hz, 1H), 6.66 (d, J = 16.5 Hz, 1H), 7.26–7.31 (m, 4H). MS *m*/*z* (relative intensity) 224 (M⁺, 5.14), 209 (100.00), 174 (1.54), 165 (41.73), 137 (14.92), 102 (13.16), 87 (13.04). Anal. Calcd for C₁₂H₁₃ClO₂: C, 64.15; H, 5.83. Found, C, 64.33; H, 6.50%.

Compound **1h**: white solid, mp 50–51 °C, 65% yield. IR (film) (cm⁻¹): 2989, 2934, 2896, 1655, 1606, 1578, 1512, 1442, 1307, 1274, 1247, 1175, 1101, 1031. ¹H NMR (CDCl₃) δ 1.56 (s, 3H),

3.81 (s, 3H), 3.94–4.02 (m, 4H), 6.02 (d, J = 18.6 Hz, 1H), 6.65 (d, J = 15.9 Hz, 1H), 6.84–6.87 (m, 2H), 7.32–7.35 (m, 2H). MS *m*/*z* (relative intensity) 220 (M⁺, 7.59), 205 (100.00), 189 (1.82), 175 (2.87), 161 (40.34), 148 (11.09), 133 (14.93), 102 (3.57), 87 (13.04). Anal. Calcd for C₁₃H₁₆O₃: C, 70.89; H, 7.32. Found, C, 70.92; H, 7.39%.

Compound **1i**: yellow liquid, 88% yield. IR (film) (cm⁻¹): 2987, 2885, 1515, 1373, 1297, 1197, 1100, 1074, 1042. ¹H NMR (CDCl₃) δ 1.58 (s, 3H), 2.35 (s, 3H), 3.93–4.05 (m, 4H), 6.12 (d, J = 16.2 Hz, 1H), 6.69 (d, J = 15.9 Hz, 1H), 7.14 (d, J = 7.8 Hz, 2H), 7.31 (d, J = 8.4 Hz, 2H). MS m/z (relative intensity) 204 (M⁺, 1.53), 189 (100.00), 173 (0.89), 159 (2.93), 145 (35.95), 117 (16.36), 91 (10.09). Anal. Calcd for C₁₃H₁₆O₂: C, 76.44; H, 7.90. Found, C, 76.65; H, 8.31%.

Compound **1***j*: yellow liquid, 95% yield. IR (film) (cm⁻¹): 2986, 2886, 1618, 1415, 1376, 1327, 1201, 1167, 1127, 1069, 1043. ¹H NMR (CDCl₃) δ 1.57 (s, 3H), 3.92–4.04 (m, 4H), 6.25 (d, J = 15.9 Hz, 1H), 6.74 (d, J = 15.9 Hz, 1H), 7.47–7.59 (m, 4H). MS *m*/*z* (relative intensity) 258 (M⁺, 5.12), 243 (100.00), 199 (47.10), 171 (20.18), 87 (18.04). Anal. Calcd for C₁₃H₁₃F₃O₂: C, 60.46; H, 5.07. Found: C, 60.51; H, 4.94%.

Compound **1k**: solid, mp 76–77 °C, 75% yield. IR (film) (cm⁻¹): 2980, 2965, 2895, 1654, 1606, 1575, 1514, 1310, 1285, 1245, 1176, 1152, 1046, 1023. ¹H NMR (CDCl₃) δ 3.80 (s, 3H), 3.98–4.12 (m, 4H), 6.22 (d, *J* = 15.9 Hz, 1H), 6.61 (d, *J* = 15.9 Hz, 1H), 6.83 (d, *J* = 8.7 Hz, 2H), 7.30–7.37 (m, 5H), 7.54–7.57 (m, 2H). MS *m*/*z* (relative intensity) 282 (M⁺, 10.82), 251 (1.20), 221 (51.04), 210 (100.00), 205 (25.77), 195 (11.03), 149 (30.15), 105 (34.19), 77 (21.94). Anal. Calcd for C₁₈H₁₈O₃: C, 76.57; H, 6.43. Found: C, 76.53; H, 6.41%.

Compound **1**I: solid, mp 61–62 °C, 77% yield. IR (film) (cm⁻¹): 2895, 1665, 1600, 1514, 1447, 1338, 1223, 1155, 1044. ¹H NMR (CDCl₃) δ 2.32 (s, 3H), 3.99–4.13 (m, 4H), 6.30 (d, J = 16.2 Hz, 1H), 6.65 (d, J = 15.9 Hz, 1H), 7.09–7.58 (m, 9H). MS *m*/*z* (relative intensity) 266 (M⁺, 36.59), 251 (0.78), 221 (47.89), 207 (100.00), 194 (84.58), 189 (35.67), 179 (46.81), 145 (42.81), 105 (39.68), 91 (22.03), 77 (50.20). Anal. Calcd for C₁₈H₁₈O₂: C, 81.17; H, 6.81; Found: C, 81.04; H, 6.87%.

Compound **1n**: pale yellow solid, mp 66–67 °C, 90% yield. IR (film) (cm⁻¹): 2890, 1658, 1592, 1489, 1332, 1219, 1160, 1049. ¹H NMR (CDCl₃) δ 3.96–4.14 (m, 4H), 6.33 (d, J = 15.9 Hz, 1H), 6.64 (d, J = 15.6 Hz, 1H), 7.23–7.60 (m, 9H). MS *m/z* (relative intensity) 286 (M⁺, 12.86), 241 (6.84), 214 (49.63), 189 (18.38), 179 (46.58), 165 (31.57), 149 (28.95), 105 (55.48), 77 (100.00). HRMS. Calcd for C₁₇H₁₅ClO₂: 286.0761. Found: 286.0766.

Compound **10**: white solid, mp 79–80 °C, 82% yield. IR (film) (cm⁻¹): 2897, 1664, 1615, 1448, 1416, 1324, 1168, 1110, 1067. ¹H NMR (CDCl₃) δ 3.98–4.14 (m, 4H), 6.45 (d, J = 15.9 Hz, 1H), 6.73 (d, J = 15.6 Hz, 1H), 7.36–7.58 (m, 9H). ¹⁹ F NMR (CDCl₃) δ –62.5 (s, 3F). MS *m*/*z* (relative intensity) 320 (M⁺, 45.41), 276 (17.89), 248 (52.70), 207 (19.99), 189 (27.60), 175 (19.98), 149 (85.63), 105 (100.00), 77 (77.41). Anal. Calcd for C₁₈H₁₅F₃O₂: C, 67.50; H, 4.72. Found: C, 67.80; H, 4.40%.

Compound **1p**, white solid, mp 70–71 °C, 82% yield. IR (film) (cm⁻¹): 2984, 2949, 2891, 1650, 1614, 1577, 1511, 1495, 1450, 1278, 1246, 1182, 1143, 1054, 1020. ¹H NMR (CDCl₃) δ 2.36 (s, 3H), 3.99–4.12 (m, 4H), 6.35 (d, J = 15.9 Hz, 1H), 6.69 (d, J = 15.9 Hz, 1H), 7.17–7.49 (m, 9H). MS *m*/*z* (relative intensity) 266 (M⁺, 21.26), 251 (0.95), 221 (51.04), 194 (100.00), 179 (55.16), 131(26.64), 119 (44.69). Anal. Calcd for C₁₈H₁₈O₂: C, 81.17; H, 6.81. Found: C, 81.16; H, 6.91%.

Compound **1q**: colorless liquid, 42%. ¹H NMR (CDCl₃) δ 3.81 (s, 3H), 3.97–4.13 (m, 4H), 6.35 (d, J = 15.9 Hz, 1H), 6.67 (d, J = 15.9 Hz, 1H), 6.88–6.91 (m, 2H), 7.23–7.40 (m, 5H), 7.47–7.50 (m, 2H). MS *m*/*z* (relative intensity) 282 (M⁺, 15.17), 210 (100.00), 205 (7.91), 179 (18.50), 175 (9.25), 131 (8.21), 103 (11.11), 77 (19.22). Anal. Calcd for C₁₈H₁₈O₃: C, 76.57; H, 6.43. Found: C, 81.16; H, 6.91%.

Synthesis of gem-difluoropropyl acetals and ketals

A typical procedure: under a nitrogen atmosphere, in a 10 ml side-armed Pyrex tube with a magnetic stirring bar and a pressure-equalized addition funnel, was placed acetal (**1a**) (1.82 g, 10.33 mmol), sodium fluoride (43 mg, 1.03 mmol) and diglyme (1 ml). After heating the mixture to about 120 °C (bath), TFDA (7.76 g, 30.98 mmol) was added dropwise. The mixture was stirred at this temperature for 1 h. Then the reaction was cooled to room temperature and directly purified by flash chromatography on a silica gel column. Title product (**2a**) (1.60 g, 68%) was obtained as a pale yellow liquid (eluent: petroleum ether–ether = 10 : 1).

Compound **2a**: liquid, IR (film) (cm⁻¹): 2893, 1679, 1504, 1475, 1448, 1259, 1217, 1176, 1021, 1003. ¹H NMR (CDCl₃) δ 2.10–2.16 (m, 1H), 2.85–2.91 (m, 1H), 3.90–4.06 (m, 4H), 5.00 (d, J = 6.0 Hz, 1 H), 7.24–7.34 (m, 5H). ¹⁹F NMR (CDCl₃) δ –134.6 (dd, J = 163.3, 15.8 Hz, 1 F), –137.0 (dd, J = 164.4, 15.5 Hz, 1 F). MS *m/z* (relative intensity) 226 (M⁺, 1.60), 207 (1.56), 183 (0.58), 164 (4.83), 153 (2.97), 133 (16.04), 77 (6.51), 73 (100.00). HRMS. Calcd for C₁₂H₁₂F₂O₂: 226.0805, Found 226.0805.

Compound **2b**: liquid, IR (film) (cm⁻¹): 2894, 1683, 1500, 1400, 1260, 1176, 1093, 1004. ¹H NMR (CDCl₃) δ 2.05–2.14 (m, 1H), 2.81–2.97 (m, 1H), 3.90–4.06 (m, 4H), 4.46 (d, J = 8.1 Hz, 0.31 H), 4.99 (d, J = 5.7 Hz, 0.69 H), 7.17–7.39 (m, 4H). ¹⁹F NMR (CDCl₃) δ –134.6 (dd, J = 163.3, 15.8 Hz, 1 F), -137.0 (dd, J = 164.4, 15.5 Hz, 1 F). MS *m*/*z* (relative intensity) 260 (M⁺, 0.55), 225 (1.76), 187 (3.67), 165 (17.66), 137 (10.63), 131 (50.33), 103 (25.60), 73 (100.00). HRMS. Calcd for C₁₂H₁₁ClF₂O₂: 260.0416, Found 260.0371. Anal. Calcd for C₁₂H₁₁F₂O₂: C, 55.29; H, 4.25; F, 14.58. Found: C, 55.49; H, 4.24; F, 14.36%.

Compound **2c**: pale yellow liquid, IR (film) (cm⁻¹): 2897, 1614, 1519, 1251, 1178, 1033. ¹H NMR (CDCl₃) δ 2.04–2.10 (m, 1H), 2.79–2.87 (m, 1H), 3.78 (s, 3H), 3.90–4.08 (m, 4H), 4.49 (d, *J* = 8.1 Hz, 0.32 H), 4.97 (d, *J* = 6.3 Hz, 0.68 H), 6.84–6.87 (m, 2H), 7.16–7.36 (m, 2H). ¹⁹F NMR (CDCl₃) δ –122.5 (dd, *J* = 165.3, 14.4 Hz, 0.32 F), -134.9 (dd, *J* = 159.0, 13.5 Hz, 0.68 F), -137.1 (dd, *J* = 163.6, 13.5 Hz, 0.68 F), -145.8 (d, *J* = 165.0 Hz, 0.32 F). MS *m*/*z* (relative intensity) 256 (M⁺, 1.73), 183 (4.48), 139 (49.32), 77 (8.52), 73 (100.00). Anal. Calcd for C₁₃H₁₄F₂O₃: C, 60.93; H, 5.51; F, 14.83. Found: C, 60.59; H, 6.02; F, 14.55%.

Compound **2d**: pale yellow liquid, IR (film) (cm⁻¹): 2959, 2893, 1521, 1473, 1402, 1328, 1259, 1220, 1175, 1098, 1026, 1004. ¹H NMR(CDCl₃) δ 2.05–2.14 (m, 1H), 2.33 (s, 3H), 2.81–2.88 (m, 1H), 3.90–4.07 (m, 4H), 4.98 (d, J = 6.0 Hz, 1H), 7.15 (s, 4H). ¹⁹F NMR (CDCl₃) δ –134.3 (dd, J = 159.6 Hz, 15.2 Hz, 1F), –136.6 (dd, J = 159.3 Hz, 14.4 Hz, 1F). MS *mlz* (relative intensity) 240 (M⁺, 1.04), 225 (0.33), 167 (1.37), 147 (4.97), 73 (100.00). Anal. Calcd for C₁₃H₁₄F₂O₂: C, 64.99; H, 5.87; F, 15.82. Found: C, 65.07; H, 5.96; F, 15.84%.

Compound **2e**: yellow liquid, IR (film) (cm⁻¹): 2964, 2897, 1686, 1623, 1584, 1525, 1476, 1413, 1329, 1262, 1169, 1127, 1070, 1021. ¹H NMR(CDCl₃) δ 2.12–2.22 (m, 1H), 2.89–2.97 (m, 1H), 3.83–4.10 (m, 4H), 7.35–7.60 (m, 4H). ¹⁹F NMR (CDCl₃) δ –134.1 (dd, J = 161.6 Hz, 13.0 Hz, 1F), -136.2 (dd, J = 162.7, 13.8 Hz, 1F), -62.60 (s, 3F). MS *m*/*z* (relative intensity) 294 (M⁺, 0.55), 293 (0.61), 275 (2.23), 232 (1.78), 221 (1.73), 201 (6.48), 145 (2.24), 73 (100.00), 69 (2.03). Anal. Calcd for C₁₃H₁₁F₅O₂: C, 53.07; H, 3.77; F, 32.29. Found: C, 52.60; H, 3.63; F, 32.53%.

Compound **2f**: liquid, IR (film) (cm⁻¹): 2989, 2891, 1670, 1609, 1504, 1446, 1327, 1221, 1039. ¹H NMR (CDCl₃) δ 1.56 (s, 3H), 2.11–2.19 (m, 1H), 2.91–2.98 (m, 1H), 3.93–4.08 (m, 4H), 7.23–7.39 (m, 5H). ¹⁹F NMR (CDCl₃) δ –133.6 (dd, *J* = 159.3, 17.2 Hz, 1 F), –135.9 (dd, *J* = 162.2, 14.9 Hz, 1 F). MS *m*/*z* (relative intensity) 240 (M⁺, 0.84), 225 (1.58), 190 (0.50), 175 (7.83), 133 (12.14), 87 (89.56), 43

(100.00). HRMS. Calcd for $C_{13}H_{14}F_2O_2{:}$ 240.0962, Found 240.0925.

Compound **2g**: liquid, IR (film) (cm⁻¹): 2988, 1891, 1672, 1612, 1593, 1493, 1464, 1220, 1091, 1039. ¹H NMR (CDCl₃) δ 1.35 (s, 3H), 2.07–2.15 (m, 1H), 2.87–2.94 (m, 1H), 3.91–4.06 (m, 4H), 7.12–7.33 (m, 4H). ¹⁹F NMR (CDCl₃) δ –133.8 (dd, J = 159.3, 15.2 Hz, 1 F), -136.5 (dd, J = 159.0, 14.1 Hz, 1 F). MS *m*/*z* (relative intensity) 274 (M⁺, 2.19), 259 (1.78), 209 (12.75), 165 (14.64), 101 (8.89), 87 (100.00). HRMS. Calcd for C₁₃H₁₃ClF₂O₂: 274.0572, Found 274.0587.

Compound **2h**: liquid, IR (film) (cm⁻¹): 2989, 2895, 1614, 1519, 1466, 1250, 1180, 1037. ¹H NMR (CDCl₃) δ 1.55 (s, 3H), 2.03–2.11 (m, 1H), 2.85–2.93 (m, 1H), 3.79 (s, 3H), 3.92–4.06 (m, 4H), 6.85–6.88 (m, 2 H), 7.14–7.17 (d, J = 8.7 Hz, 2 H). ¹⁹F NMR (CDCl₃) δ –135.0 (dd, J = 158.4, 14.7 Hz, 1 F), -137.5 (dd, J = 158.3, 13.8 Hz, 1 F). MS *m*/*z* (relative intensity) 270 (M⁺, 1.12), 255 (1.96), 235 (1.58), 183 (3.99), 163 (6.84), 87 (100.00). HRMS. Calcd for C₁₄H₁₆F₂O₃: 270.1068, Found 270.1063.

Compound **2i**: pale yellow liquid, IR (film) (cm⁻¹): 2988, 2891, 1522, 1466, 1410, 1378, 1328, 1278, 1244, 1221, 1172, 1039, 993. ¹H NMR (CDCl₃) δ 1.55 (s, 3H), 2.11 (dddd, J = 14.7, 8.7, 1.2 Hz, 1H), 2.90 (dddd, J = 14.7, 9.0, 1.2 Hz, 1H), 3.90–4.07 (m, 4H), 7.3 (s, 4H). ¹⁹F NMR (CDCl₃) δ –133.7 (dd, J = 159.0, 14.7 Hz, 1F), -136.0 (dd, J = 157.4, 14.4 Hz, 1F). MS m/z (relative intensity) 254 (M⁺, 2.60), 239 (2.08), 189 (1.94), 167 (2.10), 147 (5.79), 115 (4.80), 87 (100.00). HRMS. Calcd for C₁₄H₁₆F₂O₂: 254.1118, Found: 254.1102. Anal. Calcd for C₁₄H₁₆F₂O₂: F, 14.94. Found: F, 15.14%.

Compound **2j**: liquid, IR (film) (cm⁻¹): 2990, 1620, 1468, 1169, 1127, 1068. ¹H NMR (CDCl₃) δ 1.55 (s, 3H), 2.15–2.23 (m, 1H), 2.95–3.03 (m, 1H), 3.92–4.09 (m, 2H), 7.34–7.60 (m, 4H). ¹⁹F NMR (CDCl₃) δ –62.5 (s, 3F), –133.3 (dd, *J* = 161.0, 14.4 Hz, 1F), –136.7 (dd, *J* = 160.5, 13.5 Hz, 1F). MS *m*/*z* (relative intensity) 308 (M⁺, 1.68), 293 (6.87), 243 (100.00), 199 (49.54), 171 (18.43), 145 (11.73), 87 (93.49). Anal. Calcd for C₁₉H₁₈F₂O₃: C, 68.67; H, 5.46; F, 11.43. Found: C, 68.67; H, 5.42; F, 11.61%.

Compound **2k**: white solid, mp 59–60 °C. IR (film) (cm⁻¹): 2895, 1654, 1513, 1460, 1421, 1285, 1245, 1152, 1046. ¹H NMR (CDCl₃) δ 2.26–2.33 (m, 1H), 3.09–3.17 (m, 1H), 3.76 (s, 3H), 3.83–4.18 (m, 4H), 6.79–6.83 (m, 2H), 7.05–7.09 (m, 2H). ¹⁹F NMR (CDCl₃) δ –133.3 (dd, J = 158.1, 14.5 Hz, 1F), 136.7 (dd, J = 158.3, 14.3 Hz, 1F). MS *m*/*z* (relative intensity) 332 (M⁺, 1.11), 238 (2.30), 210 (16.79), 205 (4.99), 149 (100.00), 105 (31.77), 77 (21.96). Anal. Calcd for C₁₉H₁₈F₂O₃: C, 68.67; H, 5.46; F, 11.43. Found: C, 68.67; H, 5.42; F, 11.61%.

Compound **21**: solid, mp 40–41 °C. IR (film) (cm⁻¹): 2895, 1654, 1513, 1460, 1421, 1285, 1245, 1152, 1046. ¹H NMR (CDCl₃) δ 2.30 (s, 3H), 2.31–2.37 (m, 1H), 3.11–3.19 (m, 1H), 3.83–4.18 (m, 4H), 7.03–7.08 (m, 4H), 7.33–7.41 (m, 3H), 7.54–7.58 (m, 2H). ¹⁹F NMR (CDCl₃) δ –132.3 (dd, J = 157.9, 14.7 Hz, 1F), -135.4 (dd, J = 158.5, 13.3 Hz, 1F). MS *m*/*z* (relative intensity) 316 (M⁺, 3.04), 266 (28.87), 239 (0.80), 194 (70.88), 149 (100.00), 105 (91.34), 77 (60.80). Anal. Calcd for C₁₉H₁₈F₂O₂: C, 72.14; H, 5.74; F, 12.01. Found: C, 72.48; H, 5.92; F, 12.02%.

Compound **2m**: yellow liquid, ¹H NMR (CDCl₃) δ 2.33–2.41 (m, 1H), 3.15–3.23 (m, 1H), 3.81–4.18 (m, 4H), 7.15–7.66 (m, 10H). ¹⁹F NMR (CDCl₃) δ –131.8 (dd, J = 159.9, 14.1 Hz, 1F), –135.7 (dd, J = 161.9, 15.2 Hz, 1F). MS *m*/*z* (relative intensity) 302 (M⁺, 4.70), 252 (3.29), 207 (14.47), 149 (45.39), 105 (100.00), 77 (57.90). HRMS Calcd. for C₁₈H₁₆F₂O₂: 302.1118. Found: 302.1128.

Compound **2n**: liquid. ¹H NMR (CDCl₃) δ 2.28–2.36 (m, 1H), 3.57–3.64 (m, 1H), 3.78–4.16 (m, 4H), 7.07–7.70 (m, 9H). ¹⁹F NMR (CDCl₃) δ –131.9 (dd, J = 160.7, 13.8 Hz, 1F), –135.3 (dd, J = 158.9, 13.5 Hz, 1F). MS *m/z* (relative intensity) 336 (M⁺, 5.18), 317 (0.53), 287 (16.09), 242 (11.29), 214 (40.56), 149 (100.00), 105 (94.22), 77 (35.81). Anal. Calcd

for C₁₈H₁₅ClF₂O₂: C, 64.20; H, 4.49; F, 11.28. Found: C, 64.50; H, 4.11; F, 11.15%.

Compound **20**: liquid, IR (film) (cm⁻¹): 2896, 1686, 1621, 1486, 1413, 1327, 1168, 1127, 1069. ¹H NMR (CDCl₃) δ 2.28–2.36 (m, 1 H), 3.11–3.19 (m, 1 H), 3.76–4.12 (m, 4 H), 7.18–7.61 (m, 9 H). ¹⁹F NMR (CDCl₃) δ –62.6 (s, 3F), –131.7 (dd, J = 159.3, 16.1 Hz, 1F), –135.2 (dd, J = 159.3, 13.8 Hz, 1F). MS *m*/*z* (relative intensity) 370 (M⁺, 10.73), 320 (25.20), 248 (30.46), 149 (90.49), 105 (100.00), 77 (63.03). Anal. Calcd for C₁₉H₁₅F₅O₂: C, 61.62; H, 4.08. Found: C, 62.81; H, 3.75%.

Compound **2p**: liquid, IR (film) (cm⁻¹): 3030, 2895, 1608, 1504, 1469, 1446, 1328, 1275, 1168, 1074, 1011. ¹H NMR (CDCl₃) δ 2.33 (s, 3H), 2.33–2.41 (m, 1H), 3.14–3.21 (m, 1H), 3.82–4.14 (m, 4H), 7.16–7.32 (m, 7H), 7.43–7.46 (m, 2H). ¹⁹F NMR (CDCl₃) δ –132.2 (dd, J = 159.9, 14.4 Hz, 1F), –135.3 (dd, J = 159.3, 14.4 Hz, 1F). Anal. Calcd for C₁₉H₁₈F₂O₂: C, 72.14; H, 5.74; F, 12.01. Found: C, 72.35; H, 5.70; F, 12.26%.

Compound **2q**: white solid, mp 111–112 °C. IR (film) (cm⁻¹): 3024, 2964, 1612, 1584, 1511, 1467, 1302, 1276, 1255, 1168, 1175, 1076, 1014. ¹H NMR (CDCl₃) δ 2.37 (dddd, J = 14.4, 8.4, 0.6 Hz, 1H), 3.14 (dd, J = 14.1, 9.0 Hz, 1H), 3.82 (s, 3H), 3.85– 4.14 (m, 4H), 6.88–6.92 (m, 2H), 7.16–7.32 (m, 5H), 7.46–7.50 (m, 2H). ¹⁹F NMR (CDCl₃) δ –132.2 (dd, J = 158.2, 14.7 Hz, 1F), –135.3 (dd, J = 158.2, 14.7 Hz, 1F). MS *m*/*z* (relative intensity) 332 (M⁺, 0.59), 301 (2.38), 252 (0.58), 237 (2.72), 221 (0.98), 192 (100.00), 179 (78.48), 135 (62.57), 107 (6.53), 77 (13.35). Anal. Calcd for C₁₉H₁₈F₂O₃: C, 68.67; H, 5.46; F, 11.43. Found: C, 68.57; H, 5.39; F, 11.36%.

Hydrolysis of *gem*-difluorocyclopropyl derivatives 2 under acidic conditions

A typical procedure: a 25 ml flask with a water condenser and a magnetic stirring bar was charged with **2a** (1.54 g, 6.8 mmol), 5 ml of saturated oxalic solution and 5 ml of dioxane, the mixture was heated to 110 °C and stirred for 6 h. After cooling to room temperature the content was extracted with ether. The organic layer was dried over Na_2SO_4 . After removal of solvent under reduced pressure, the residue was purified by flash chromatography on silica gel column. 3-Fluoro-2-phenylfuran (**4a**) (0.23 g, 21%) was obtained as pale yellow liquid.

Compound **4a**: liquid, IR (film) (cm⁻¹): 3059, 1633, 1602, 1510, 1490, 1433, 1281, 1267, 1113, 1066. ¹H NMR (CDCl₃) δ 6.40–6.41 (m, 1H), 7.21–7.27 (m, 2H), 7.37–7.43 (m, 2 H), 7.67–7.70 (m, 2H). ¹⁹F NMR (CDCl₃) δ – 165.3 (s, 1F). MS *m/z* (relative intensity) 162 (M⁺, 6.62), 133 (11.83), 121 (6.75), 105 (100.00), 77 (93.15). Anal. Calcd for C₁₀H₇FO: C, 74.07; H, 4.35; F, 11.72. Found: C, 73.90; H, 4.24; F, 11.43%.

Compound **4b**: liquid, IR (film) (cm⁻¹): 1631, 1568, 1507, 1486, 1435, 1400, 1278, 1265, 1168, 1086. ¹H NMR (CDCl₃) δ 6.42–6.43 (m, 1H), 7.23–7.26 (m, 1H), 7.36–7.39 (m, 2 H), 7.58–7.62 (m, 2H). ¹⁹F NMR (CDCl₃) δ –164.4 (s, 1F). MS *m*/*z* (relative intensity) 196 (M⁺, 100.00), 167 (31.74), 161 (2.09), 133 (52.59), 77 (93.15). Anal. Calcd for C₁₀H₆CIFO: C, 61.09; H, 3.08; F, 9.66. Found: C, 61.14; H, 2.94; F, 9.47%.

Compound **4c**: liquid, IR (film) (cm⁻¹): 2960, 2839, 1639, 1608, 1575, 1520, 1496, 1437, 1301, 1252, 1118, 1087, 1037. ¹H NMR (CDCl₃) δ 3.82 (s, 3H), 6.39–6.40 (m, 1H), 6.93–6.96 (m, 2H), 7.18–7.20 (m, 1H), 7.60–7.63 (m, 2H). ¹⁹F NMR (CDCl₃) δ – 168.0 (s, 1F). MS *m/z* (relative intensity) 192 (M⁺, 100.00), 177 (10.83), 151 (46.75), 107 (13.15). HRMS Calcd for C₁₁H₉FO₂: 192.0587; Found: 192.0590.

Compound **4d**: liquid, IR (film) (cm⁻¹): 2924, 1683, 1635, 1607, 1520, 1436, 1410, 1327, 1266, 1228, 1185, 1089. ¹H NMR (CDCl₃) δ 2.36 (s, 3H), 6.40–6.41 (m, 1H), 7.20–7.23 (m, 3H), 7.58 (d, J = 8.1 Hz, 2H). ¹⁹F NMR (CDCl₃) δ –166.0 (s, 1F). MS *m*/*z* (relative intensity) 176 (M⁺, 100.00), 147 (35.31), 133 (29.21). Anal. Calcd for C₁₁H₉FO: C, 74.99; H, 5.15; F, 10.78. Found: C, 74.78; H, 4.94; F, 10.74%.

Compound **4e**: liquid, ¹H NMR (CDCl₃) δ 6.39 (m, 1H), 7.19 (d, J = 0.6 Hz, 1H), 7.24 (m, 1H), 7.57–7.60 (m, 2H), 7.70–7.73 (m, 2H). ¹⁹F NMR (CDCl₃) δ –161.8 (d, J = 4.2 Hz).

Compound **3e**: liquid, IR (film) (cm⁻¹): ¹H NMR (CDCl₃) δ 2.97–3.06 (m, 1H), 3.63–3.69 (m, 1H), 7.37–7.40 (m, 2H), 7.62–7.69 (m, 2H), 9.55 (m, 1H). ¹⁹F NMR (CDCl₃) δ – 166. MS *m/z* (relative intensity) 250 (M⁺, 0.51), 231 (4.04), 221 (100.00), 201 (83.71), 181 (12.22), 151 (68.41), 131 (73.80), 69 (3.01). Anal. Calcd for C₁₁H₇F₅O: C, 52.81; H, 2.82. Found: C, 53.31; H, 3.57%.

Compound **4f**: liquid, IR (film) (cm⁻¹): 2924, 1683, 1635, 1607, 1520, 1436, 1410, 1327, 1266, 1228, 1185, 1089. ¹H NMR (CDCl₃) δ 2.31 (s, 3H), 6.03–6.05 (m, 1H), 7.18–7.25 (m, 1H), 7.35–7.40 (m, 2H), 7.62–7.66 (m, 2H). ¹⁹F NMR (CDCl₃) δ –162.8 (s, 1F). MS *m/z* (relative intensity) 176 (M⁺, 100.00), 147 (15.30), 133 (40.55), 105 (24.20), 77 (29.77). HRMS Calcd for C₁₁H₉FO: 176.0637; Found: 176.0654.

Compound **4g**: liquid, ¹H NMR (CDCl₃) δ 2.31 (s, 3H), 6.04– 6.05 (m, 1H), 7.33–7.37 (m, 2H), 7.55–7.59 (m, 2H). ¹⁹F NMR (CDCl₃) δ –162.3 (s, 1F).

Compound **3g**: liquid, IR (cm⁻¹): 1716, 1500, 1453, 1402, 1362, 1331, 1286, 1221, 1181, 1155, 1092, 1016. ¹H NMR (300 MHz, CDCl₃): δ 2.40 (s, 3H), 2.95–3.02 (m, 1H), 3.52–3.60 (m, 1H), 7.15–7.18 (m, 2H), 7.30–7.34 (m, 2H). MS *m/z* (relative intensity) 230 (M⁺, 0.91), 210 (4.51), 187 (79.13), 167 (57.40), 151 (27.80), 111 (2.76), 43 (100.00). Anal. Calcd for C₁₁H₉ClF₂O: C, 57.28; H, 3.93; F, 16.47. Found: C, 57.32; H, 4.03; F, 16.74%.

Compound **4h**: liquid. IR (cm⁻¹): 3003, 2957, 1646, 1611, 1583, 1570, 1511, 1463, 1442, 1410, 1303, 1255, 1180, 1145, 1040. ¹H NMR (300 MHz, CDCl₃): δ 2.29 (s, 3H), 3.82 (s, 3H), 6.01 (s, 1H), 6.91–6.94 (m, 2H), 7.55–7.58 (m, 2H). ¹³C NMR (500 MHz, CDCl₃): δ 14.11, 55.11, 100.43, 114.01, 122.36, 124.20, 134.55, 148.52. MS *m*/*z* (relative intensity) 206, 191, 175, 163. HRMS Calcd for C₁₂H₁₁FO₂: 206.0743. Found: 206.0714.

Compound **4i**: colorless liquid, IR (film) (cm⁻¹): 2923, 1640, 1580, 1511, 1451, 1406, 1300, 1255, 1146. ¹H NMR (CDCl₃) δ 2.32 (s, 3H), 2.37 (3, 3H), 6.04 (t, J = 1.2 Hz, 1H), 7.21 (d, J = 7.8 Hz, 2H), 7.54–7.57 (m, 2H). ¹⁹F NMR (CDCl₃) δ –163.9 (s, 1F). MS *m*/*z* (relative intensity) 190 (M⁺, 100.00), 189 (47.53), 175 (8.55), 147 (38.82), 91 (17.65). Anal. Calcd for C₁₂H₁₁FO: C, 75.77; H, 5.83; F, 9.99. Found C, 75.73; H, 5.82; F, 10.09%.

Compound **3***j*: yellow liquid, IR (film) (cm⁻¹): 3017, 1718, 1623, 1526, 1456, 1411, 1364, 1328, 1287, 1224, 1168, 1128, 1071, 1018. ¹H NMR (CDCl₃) δ 2.43 (s, 3H), 3.03–3.11 (m, 1H), 3.61–3.69 (m, 1H), 7.36 (d, J = 8.4 Hz, 2H), 7.61 (d, J = 8.1 Hz, 2H). ¹⁹F NMR (CDCl₃) δ –32.5–132.4 (m, 2F), –62.7 (s, 3F). MS *m*/*z* (relative intensity) 265 (M⁺ + 1, 0.56), 245 (0.46), 221 (3.19), 201 (7.71), 195 (1.08), 151 (6.98), 43 (100.00). Anal. Calcd for C₁₂H₉F₅O: C, 54.56; H, 3.43; F, 35.96. Found: C, 54.25; H, 3.28; F, 35.80%.

Compound **4k**, white solid, mp 70–71 °C. IR (film) (cm⁻¹): 2965, 1633, 1574, 1507, 1412, 1247, 1179, 1041. ¹H NMR (CDCl₃) δ 3.85 (s, 3H), 6.64 (d, J = 0.9 Hz, 1H), 6.90–7.00 (m, 2H), 7.25–7.43 (m, 3H), 7.67–7.71 (m, 4H). ¹⁹F NMR (CDCl₃) δ – 164.2 (s, 1F). MS *m*/*z* (relative intensity) 268 (M⁺, 100.00), 253 (85.33), 225 (29.78), 196 (6.43), 176 (8.15), 77 (9.64). Anal. Calcd for C₁₇H₁₃FO₂: C, 76.11; H, 4.88; F, 7.08. Found: C, 76.12; H, 4.88; F, 6.99%. X-Ray crystallographic data: † C₁₇H₁₃-FO₂, $M_r = 268.27$; crystal system, monoclinic; space group, P2(1)/c; unit cell dimensions, a = 3.9188 (8) Å, b = 30.250 (6) Å, c = 11.013 (2) Å, $a = 90^{\circ}$, $\beta = 100.187$ (4)°, $\gamma = 90^{\circ}$; V = 1284.9 (5) Å³; Z = 4; $D_x = 1.387$ g cm⁻³; λ (Mo-K α) = 0.7153 Å; $\mu = 1.00$ cm⁻¹; *F*(000) = 560; T = 293 (2) K; GoF = 0.823; $R_{int} = 0.0775$;

[†] CCDC reference numbers 200171. See http://www.rsc.org/suppdata/ ob/b2/b212232d/ for crystallographic data in .cif or other electronic format.

 $wR(F^2) = 0.0803$ for 7845 reflections and 234 parameters and R(F) = 0.0425. †

Compound **4**I: solid, mp 88–89 °C. IR (film) (cm⁻¹): 2921, 1631, 1596, 1508, 1483, 1451, 1429, 1406, 1317, 1261, 1149, 1110. ¹H NMR (CDCl₃) δ 2.31 (s, 3H), 6.59 (d, J = 0.9 Hz, 1H), 7.16–7.25 (m, 3H), 7.31–7.36 (m, 2H), 7.60–7.64 (m, 3H). ¹⁹F NMR (CDCl₃) δ –162.4 (s, 1F). MS *m*/*z* (relative intensity) 252 (M⁺, 100.00), 237 (1.87), 223 (3.84), 209 (11.17), 191 (5.16), 175 (0.57), 147 (7.34), 133 (8.05), 77 (2.89). HRMS. Calcd for C₁₇H₁₃FO: 252.0950. Found: 252.0972. Anal. Calcd for C₁₇H₁₄F₂O: C, 80.93; H, 5.19. Found: C, 80.77; H, 5.32%.

Compound **3**I: solid, mp 92–93 °C. IR (film) (cm⁻¹): 3030, 2927, 1679, 1597, 1521, 1450, 1407, 1326, 1286, 1226, 1164, 1043. ¹H NMR (CDCl₃) δ 2.35 (s, 3H), 3.58–3.65 (m, 1H), 3.79–3.85 (m, 1H), 7.16–7.23 (m, 2H), 7.51–7.67 (m, 3H), 8.03–8.06 (m, 2H). ¹⁹F NMR (CDCl₃) δ –132.2 (m, 2F). MS *m*/*z* (relative intensity) 272 (M⁺, 0.87), 252 (0.66), 225 (29.78), 167 (6.29), 105 (100.00), 91 (2.61), 77 (25.94). Anal. Calcd for C₁₇H₁₄F₂O: C, 74.99; H, 5.18; F, 13.95. Found: C, 74.88; H, 5.15; F, 13.70%.

Compound **3m**: solid, mp 60–61 °C. IR (film) (cm⁻¹):. ¹H NMR (CDCl₃) δ 3.61–3.69 (m, 1H), 3.82–3.91 (m, 1H), 7.29– 7.67 (m, 8H), 8.03–8.07 (m, 2H). ¹⁹F NMR (CDCl₃) δ –132.6 (d, *J* = 5.1 Hz, 2F). MS *m*/*z* (relative intensity) 258 (M⁺, 0.71), 238 (0.63), 209 (0.76), 105 (100.00), 77 (40.33). HRMS. Calcd for C₁₆H₁₂F₂O: 258.0856. Found: 258.0877.

Compound **3n**: mp 84–85 °C. IR (film) (cm⁻¹): 3030, 1680, 1596, 1498, 1449, 1400, 1324, 1289, 1226, 1116, 1097, 1053, 1017. ¹H NMR (CDCl₃) δ 3.57–3.65 (m, 1H), 3.79–3.86 (m, 1H), 7.24–7.28 (m, 2H), 7.32–7.36 (m, 2H), 7.51–7.57 (m, 4H), 8.03–8.06 (m, 1H). ¹⁹F NMR (CDCl₃) δ –131.8 (t, *J* = 6.9 Hz, 2F). MS *mlz* (relative intensity) 292 (M⁺, 1.54), 272 (0.58), 187 (1.11), 167 (3.60), 151 (9.33), 105 (100.00), 77 (39.30). Anal. Calcd for C₁₆H₁₁ClF₂O: C, 65.65; H, 3.79; F, 12.98. Found: C, 65.51; H, 3.84; F, 13.24%.

Compound **30**: solid, mp 61–62 °C. IR (film) (cm⁻¹): 1687, 1621, 1452, 1329, 1169, 1069, 1137. ¹H NMR (CDCl₃) δ 3.67–3.72 (m, 1H), 3.89–4.92 (m, 1H), 7.44–7.69 (m, 7H), 8.04–8.07 (m, 2H). ¹⁹F NMR (CDCl₃) δ –62.6 (s, 3 F), –132.0 (m, 2F). MS *m*/*z* (relative intensity) 326 (M⁺, 1.52), 307 (1.24), 221 (1.07), 208 (6.50), 151 (13.29), 105 (100.00), 77 (42.49), 69 (1.22). Anal. Calcd for C₁₇H₁₁F₅O: C, 62.58; H, 3.40; F, 29.11. Found: C, 61.91; H, 3.34; F, 29.44%.

Compound **4p**: solid, mp 60–61 °C. IR (film) (cm⁻¹): 2920, 1632, 1598, 1501, 1428, 1318, 1150, 1043, 1009. ¹H NMR (CDCl₃) δ 2.38 (s, 3H), 6.61 (d, *J* = 1.2 Hz, 1H), 7.20–7.28 (m, 3H), 7.40–7.45 (m, 2H), 7.74–7.77 (m, 2H). ¹⁹F NMR (CDCl₃) δ – 161.4 (s, 1F). MS *m*/*z* (relative intensity) 252 (M⁺, 100.00), 237 (1.72), 223 (1.72), 209 (12.74), 147 (9.43), 77 (7.57). HRMS. Calcd for C₁₇H₁₃FO: 252.0950. Found: 252.0978.

Compound **3p**: white solid, mp 98–99 °C. IR (film) (cm⁻¹): 3045, 1673, 1607, 1506, 1462, 1436, 1333, 1285, 1231, 1185, 1170, 1048, 1000. ¹H NMR (CDCl₃) δ 2.45 (s, 3H), 3.59–3.66 (m, 1H), 3.80–3.89 (m, 1H), 7.29–7.39 (m, 7H), 7.94–7.96 (m, 2H). ¹⁹F NMR (CDCl₃) δ –132.3–132.2 (m, 2F). MS *m/z* (relative intensity) 272 (M⁺, 2.87), 257 (1.29), 237 (0.54), 222 (0.30), 151 (6.84), 119 (100.00), 91 (27.36), 77 (3.06). Anal. Calcd for C₁₇H₁₄F₂O: C, 74.99; H, 5.18; F, 13.95. Found: C, 74.94; H, 5.10; F, 13.79%.

Compound 4q: solid, mp 66–67 °C. IR (film) (cm⁻¹): 2961, 1630, 1583, 1501, 1431, 1305, 1253, 1046. ¹H NMR (CDCl₃) δ 3.86 (s, 3H), 6.54 (d, J = 0.6 Hz, 1H), 6.94–6.97 (m, 2H), 7.25– 7.27 (m, 1H), 7.40–7.45 (m, 2H), 7.62–7.76 (m, 4H). ¹⁹F NMR (CDCl₃) δ –161.4 (s, 1F). MS *m*/*z* (relative intensity) 268 (M⁺, 100.00), 253 (66.00), 225 (13.34), 196 (9.86), 176 (5.36), 134 (9.91), 105 (7.40), 77 (16.51). HRMS. Calcd for $C_{17}H_{13}FO_2$: 268.0900. Found: 268.0930.

Compound **3q**: solid, mp 79–80 °C. IR (film) (cm⁻¹): 3030, 1668, 1601, 1573, 1511, 1459, 1452, 1318, 1291, 1260, 1172, 1028. ¹H NMR (CDCl₃) δ 3.56–3.62 (m, 1H), 3.80–3.85 (m, 1H), 3.90 (s, 3H), 6.99–7.01 (m, 2H), 7.31–7.39 (m, 4H), 8.02–8.05 (m, 2H). ¹⁹F NMR (CDCl₃) δ –132.4––132.3 (m, 2F). MS *m*/*z* (relative intensity) 288 (M⁺, 7.44), 257 (0.28), 221 (0.82), 182 (6.31), 167 (2.56), 135 (100.00), 107 (7.63), 77 (19.12). Anal. Calcd for C₁₇H₁₄F₂O₂: C, 70.83; H, 4.89; F, 13.18. Found: C, 70.81; H, 4.93; F, 13.02%.

Acknowledgement

We thank Professor H. M. Wu for instructive advice on structure determination and Natural Science Foundation of China (D20032010) for support of this work.

References

- (a) Chemistry of Organic Fluorine Compounds II, ed. M. Hudlický and A. E. Pavlath, American Chemical Society, Washington, DC, 1995; (b) D. L. S. Brahams and W. P. Dailey, Chem. Rev., 1996, 96, 1585–1632; (c) M. R. C. Gerstenberger and A. Haas, Angew. Chem., Int. Ed. Engl., 1981, 20, 647–667; (d) M. J. Tozer and T. F. Herpin, Tetrahedron, 1996, 26, 8619–8683.
- 2 (a) V. P. Erbes and W. Boland, *Helv. Chim. Acta*, 1992, **75**, 766–772;
 (b) A. Medaghri-alaoui, H. Choukroun, P. Calas, C. Amatore and A. Commeyras, *J. Fluorine Chem.*, 1991, **1–3**, 71.
- 3 C. Beard and N. H. Fried, Tetrahedron Lett., 1966, 22, 3281.
- 4 (a) Y. Kobayashi, T. Taguchi, M. Mamada, H. Shimizu and H. Murohashi, *Chem. Pharm. Bull.*, 1979, **27**, 3123; (b) Y. Kobayashi, T. Taguchi, T. Morikawa, T. Takase and H. Takanashi, *Tetrahedron Lett.*, 1980, **21**, 1047; (c) Y. Kobayashi, T. Taguchi, T. Terada, J. Oshida, M. Morisaki and N. Ikekawa, *Tetrahedron Lett.*, 1979, **20**, 2023; (d) Y. Kobayashi, T. Morikawa, A. Yoshizawa and T. Taguchi, *Tetrahedron Lett.*, 1981, **22**, 5297; (e) Y. Kobayashi, T. Taguchi, T. Morikawa, T. Takase and H. Takanashi, J. Org. *Chem.*, 1982, **47**, 3232.
- 5 F. Tian, V. K. Kruger, O. Bautista, J.-X. Duan, A.-R. Li, W. R. Dolbier Jr. and Q.-Y. Chen, *Org. Lett.*, 2000, **2**, 563–564.
- 6 T. Itoh, N. Ishida, K. Mitsukura and K. Uneyama, J. Fluorine Chem., 2001, 112, 63-68.
- 7 W. Xu and Q.-Y. Chen, J. Org. Chem., 2002, 67, 9421-9427.
- 8 (a) R. B. Woodward, F. E. Bader, H. Bickel, A. J. Frey and R. W. Kierstead, J. Org. Chem., 1958, 2, 1; (b) H. B. Henbest, W. R. Jackson and I. Malunowicz, J. Chem. Soc. (C), 1967, 2469; (c) I. Salazar and E. Dfaz, Tetrahedron, 1979, 815–818.
- 9 O. G. Kulinkovic, I. G. Tishchenko and N. A. Roslik, J. Org. Chem. (USSR), 1984, 480–484.
- 10 (a) W. R. Dolbier Jr., Acc. Chem. Res., 1981, 14, 195; (b) S. J. Getty, D. A. Hrovat and W. T. Borden, J. Am. Chem. Soc., 1994, 116, 1521.
- 11 (a) E. Brenna, N. Caraccia, C. Fuganyi, D. Fuganti and P. Grasselli, *Tetrahedron. Asymmetry*, 1997, 3801–3805; (b) H.-J. Knőlker, B. Ahrens, P. Gonser, M. Heininger and G. Jones, *Tetrahedron*, 2000, 2259–2271; (c) V. Shadakshari and S. K. Nayak, *Tetrahedron*, 2001, 8185–8188.
- 12 P. A. Jacobi, J. I. Kravitz and W. J. Zheng, *J. Org. Chem.*, 1995, 376. 13 1,3-Dioxan-2-ylmethyltriphenylphosphonium bromide was prepared as follows: a mixture of (80 g, 479 mmol) and triphenylphosphine (125 g, 476 mmol) in anhydrous acetonitrile (250 ml) was heated to reflux for 24 h. The solvent was removed and the residue was dissolved in dichloromethane (100 ml) and diluted with ether. The precipitated solid was collected by filtration, washed with dry ether and dried under vacuum to give the salt (164 g, 80% yield).
- 14 M. Kuse and M. Isobe, *Tetrahedron*, 2000, 2629–2639.
- H. J. Dauben Jr., B. Löken and H. J. Ringold, J. Am. Chem. Soc., 1954, 1359–1362.
 J. R. Dimmock and L. M. Smith, J. Pharm. Sci., 1980, 575–580.
- 17 B. B. Lohray, T. H. Kalantar, B. M. Kim, C. Y. Park and T. Shibata, *Tetrahedron Lett.*, 1989, 2041–2044.